NEU.AU Neuren Pharmaceuticals Ltd

Healthcare Pharmaceuticals Australian Securities Exchange
20.36 AUD
Close of Nov 1, 2026
10.92 23.59
Market cap
AUD 2.58B
P/E
127.3x
P/B
7.74x
ROE
5.8%
Dividend yield
1.47%
Fundamental score
1.4/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is NEU.AU undervalued?

Graham number

The Graham number of Neuren Pharmaceuticals Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neuren Pharmaceuticals Ltd fundamental analysis

7 of 22 checks passed

ROE 0/2

Low return on equity (5.8%), below 10%.

ROA 1/1

Return on assets (5.7%) is above the industry median (-8.9%).

Profit Consistency 1/2

Profitable for 4 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-78.6%) is below the industry median (42.8%).

Revenue Growth 2/2

Revenue grew 64.4% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

No interest expense reported.

PE vs Market 0/1

PE (127.3x) is above the market median (15.0x).

PE vs Industry 0/1

PE (127.3x) is above the industry median (21.9x).

PBV 0/1

Price to book (7.7x) is above the industry median (2.0x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 985.2, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Neuren Pharmaceuticals Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neuren Pharmaceuticals Ltd

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial…

Full company profile